Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Preliminary results from a study of a peptidic extract in atopic dermatitis have revealed a third potential application originating from Advitech's XP-828L platform.
Subscribe to our email newsletter
The peptidic extract demonstrated significant results in reducing in vitro and in vivo IL-4 production by immune cells. The general consensus is that atopic dermatitis, or eczema, is an immune-mediated skin disease characterized by a predominance of IL-4 leading to IgE production resulting in inflammation.
Further studies are in progress in order to confirm the efficacy of the product against atopic dermatitis.
Advitech said the results confirm the company’s objective to commercially develop additional applications originating from its XP-828L research platform. The company has previously announced positive preclinical and clinical results on psoriasis and positive preclinical results on irritable bowel disease from compounds originating from this platform.
The psoriasis application is presently commercialized under the brand name Dermylex, an orally administered product indicated for mild to moderate plaque psoriasis made.